This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital myasthenic syndromeCongenital Myasthenic Syndrome (CMS)

Contents and key points
ItemDetails
A. Classification codesICD-10: G70.2 | Special Copayment Reduction: V012 | Coverage period: 5 years
B. SynonymsCongenital myasthenic syndrome (CMS), congenital myasthenia, hereditary neuromuscular junction disorder, familial infantile myasthenia
C. Adult onsetLikelihood of first onset in adulthood: low — most cases begin in the neonatal period to childhood; some subtypes (GFPT1 · DOK7, etc.) may first present in adulthood
1. History1937: Rothbart described familial infantile myasthenia; 1970s–80s: CMS established as a distinct entity through ultrastructural studies of the neuromuscular junction; gene discovery accelerated thereafter
2. CausesMutations in genes for neuromuscular junction proteins (CHRNA1 · CHRNB1 · CHRND · CHRNE, RAPSN, COLQ, DOK7, GFPT1, etc., more than 35); not autoimmune
3. GeneticsMostly autosomal recessive (AR); some autosomal dominant (AD, SNAP25 · SYT2 · VAMP1); more than 35 genes; confirmed by standard gene panel testing
4. General epidemiologyPrevalence about 9–14 per 1,000,000 (Western countries); incidence about 1–2 per 500,000 births; occurs worldwide; frequency by causative gene varies by region and ethnicity
5. PathophysiologyMutations in presynaptic · synaptic basal lamina · postsynaptic proteins → reduced safety factor of neuromuscular transmission; subtype-specific defects of synaptic structure, transmitter, or receptor function
6. SymptomsNeonatal hypotonia, feeding difficulty, respiratory distress; in childhood muscle fatigue, ptosis, limb weakness; worsening with fever · infection; diverse clinical spectrum by subtype
7. SignsPtosis, external ophthalmoplegia, hypotonia, fatigable limb weakness, reduced tendon reflexes; COLQ subtype: paradoxical worsening with AChE inhibitors
8. ScreeningSuspect CMS in neonatal/pediatric hypotonia + fatigable weakness; gene panel testing after confirming negative antibodies; repetitive nerve stimulation test
9. DiagnosisNegative serum AChR · MuSK antibodies, repetitive nerve stimulation test, single-fiber electromyography, ultrastructural analysis of the neuromuscular junction (if needed), next-generation sequencing (NGS)
10. TreatmentSubtype-specific treatment essential; AChE inhibitors (CHRNE · RAPSN, etc.), salbutamol · ephedrine (DOK7 · COLQ), 3,4-DAP (presynaptic type); AChE inhibitors contraindicated in COLQ type
11. PrognosisVaries by subtype; function can improve with treatment in most; some require long-term respiratory support; stable or slowly progressive in adulthood; regular respiratory function monitoring important
12. PreventionGenetic counseling; prenatal diagnosis (high-risk families); early neonatal detection; empirical AChE inhibitor administration without subtype confirmation must be avoided (risk of worsening in some subtypes)
References10 key references (including PMID/DOI)

1. History

The concept of congenital myasthenic syndrome (CMS) was gradually established as a hereditary neuromuscular junction disease distinct from autoimmune myasthenia gravis (MG). Rothbart's 1937 report of familial myasthenia with onset in the neonatal period is one of the early descriptions. In the 1950s–60s, familial infantile myasthenia and autoimmune MG were not yet clearly distinguished, and the two diseases were provisionally differentiated by their response to anticholinesterase treatment.

In the 1970s–80s, as Andrew Engel and others applied electron microscopic ultrastructural analysis of the neuromuscular junction and microelectrode electrophysiological techniques, CMS was revealed to be a heterogeneous group of disorders due to presynaptic, synaptic basal lamina, and postsynaptic defects. In the late 1980s to early 1990s, mutations in the acetylcholine receptor AChR genes (CHRNA, CHRNB, CHRND, CHRNE) were first identified as a cause of CMS, opening the era of gene-level diagnosis. Subsequently, causative genes such as COLQ (1998), RAPSN (1999), DOK7 (2006), and GFPT1 (2011) were discovered in succession, and as of 2025 more than 35 CMS-causing genes have been reported. With the spread of next-generation sequencing (NGS) technology, the genetic diagnostic yield in CMS patients of unknown cause has improved greatly.

2. Causes

CMS is a hereditary disease caused by mutations in genes encoding proteins involved in the structure and function of the neuromuscular junction (NMJ). No autoimmune mechanism is involved, and no autoantibodies are detected.

Causative genes are broadly classified into three groups according to their location.

Presynaptic genes: CHAT (choline acetyltransferase), SLC5A7 (high-affinity choline transporter), SNAP25, SYT2, VAMP1, etc. They cause defects in ACh synthesis, storage, and release. They are generally rare and tend to cause severe clinical symptoms.

Synaptic basal lamina genes: COLQ (collagen Q), LAMB2 (laminin beta 2). COLQ mutations cause deficiency of collagen Q, the protein that anchors acetylcholinesterase (AChE) to the synaptic basal lamina, leading to excessive accumulation of ACh in the synaptic cleft and desensitization. Use of AChE inhibitors is contraindicated in the COLQ type.

Postsynaptic genes: CHRNA1, CHRNB1, CHRND, CHRNE (AChR subunits), RAPSN (rapsyn), DOK7, MUSK, LRP4, SCN4A, GFPT1, etc. They disrupt neuromuscular transmission through various mechanisms, including AChR deficiency, kinetic abnormalities (slow-channel or fast-channel syndrome), and impaired endplate AChR clustering. CHRNE mutations account for about 30–50% of all CMS and are the most common. RAPSN mutations (N88K is a common founder mutation) account for about 15–20%. DOK7 mutations show a distinctive phenotype with predominantly proximal limb involvement and few ocular symptoms.

3. Genetics

More than 35 genes causing CMS are known, and the mode of inheritance is mostly autosomal recessive (AR). Exceptionally, some genes follow an autosomal dominant (AD) mode of inheritance (e.g., some AD mutations of CHRNA1 · CHRNB1 causing slow-channel syndrome, and presynaptic protein genes such as SNAP25, SYT2, and VAMP1).

The features of the main genes are summarized as follows: CHRNE (AR, most common, ~30–50%): a specific founder mutation (ε1267delG) at high frequency in southern Mediterranean and Gypsy (Roma) populations. RAPSN (AR, ~15–20%): N88K founder mutation common in people of European descent; respiratory crises possible from the neonatal period. DOK7 (AR): limb-girdle weakness, mild bulbar involvement, worsening with AChE inhibitors, response to salbutamol/ephedrine. COLQ (AR): impaired anchoring of AChE to the basal lamina; AChE inhibitors contraindicated. Glycosylation-related genes such as GFPT1 · GMPPB · ALG (AR): possible first onset in adulthood, predominantly proximal limb involvement. Slow-channel syndrome (CHRNA · CHRNB, etc., AD): distinctive repetitive electromyographic findings (doublet discharges); treated with quinidine · fluoxetine.

Genetic testing: When CMS is clinically suspected, CMS panel NGS (next-generation sequencing) is performed after confirming negative AChR · MuSK antibodies. Whole exome sequencing (WES) or whole genome sequencing (WGS) is additionally used in panel-negative patients.

4. General epidemiology

The exact prevalence of CMS is difficult to determine given its rarity, but estimates in Western countries are about 9–14 per 1 million population. In a study in the UK, the birth incidence was estimated at about 1–2 per 500,000 births. It occurs worldwide, and the frequency by causative gene differs by ethnicity and region.

For example, CHRNE mutations are frequent in southern Mediterranean and Gypsy (Roma) populations, and the RAPSN N88K founder mutation is common in people of European descent. DOK7 mutations are one of the second most common causes of CMS worldwide. There is no sex bias for most AR genes, but slow-channel syndrome is reported with a slight male predominance. Diagnosis is often delayed, and adult-onset subtypes in particular (GFPT1, etc.) may be misdiagnosed as acquired neuropathy or myopathy.

5. Pathophysiology

The pathogenesis of CMS is a reduction in the safety factor of neuromuscular transmission due to defects in specific proteins of the neuromuscular junction. The mechanism differs by subtype, and treatment response differs accordingly.

Presynaptic defects: Impaired ACh synthesis (CHAT deficiency), storage (vesicle protein defects), or release (SNAP25 · SYT2 defects) reduces the amount of ACh released per nerve impulse (quantal content). It worsens further with repetitive stimulation.

Synaptic basal lamina defects (COLQ type): When AChE anchored in the basal lamina is deficient, ACh accumulates excessively in the synaptic cleft. This causes AChR desensitization, and ion channel overload of the postsynaptic membrane leads to endplate myopathy. This is why AChE inhibitors cause paradoxical worsening by further accumulating ACh.

Postsynaptic defects: AChR deficiency (CHRNE · RAPSN, etc.): reduced AChR number decreases the amplitude of miniature endplate potentials (MEPP). Slow-channel syndrome (CHRNA, etc., AD): abnormally prolonged ion channel opening time causes calcium overload and endplate degeneration. Fast-channel syndrome (CHRNE · CHRND): shortened channel opening time reduces transmission efficiency. DOK7 type: reduced MuSK activation causes defective AChR clustering and simplification of synaptic structure.

6. Symptoms

In CMS, age of onset, distribution of affected muscles, and symptom severity vary greatly depending on the causative gene and mutation. The common feature is motor weakness that worsens with fatigue.

Neonatal symptoms: Neonatal hypotonia (floppy infant), feeding difficulty, weak cry, apnea · respiratory failure. Severe neonatal presentation is particularly common in the RAPSN and CHAT types. Respiratory crises can be triggered by infection or fever and are life-threatening.

Childhood symptoms: Delayed motor development, difficulty climbing stairs, rapid fatigue with running and physical activities, ptosis, diplopia. The DOK7 type shows prominent proximal shoulder-girdle and pelvic-girdle weakness with mild ocular symptoms. The COLQ type shows a variable mix of ptosis, ophthalmoplegia, and generalized weakness.

Adult onset (some subtypes): Glycosylation gene mutation types such as GFPT1 and GMPPB may first present in adulthood (20s–40s). Proximal limb weakness, fatigable weakness, sometimes accompanied by lymphedema (GFPT1 type).

Aggravating factors: Fever, infection, emotional stress, certain drugs (magnesium, aminoglycosides, neuromuscular blockers). Worsening with fever is a typical feature of CMS, especially prominent in the RAPSN and COLQ types.

7. Signs

Physical examination findings in CMS are similar to those in MG, but CMS is distinguished by negative autoantibodies and onset in the neonatal period to childhood.

Ocular signs: Ptosis (unilateral or bilateral), external ophthalmoplegia, diplopia. In the DOK7 type, ocular involvement is relatively mild. Ptosis may be prominent in slow-channel syndrome.

Pattern of weakness: Varies by subtype. Generalized type, bulbar-cervical predominant type, proximal limb predominant type (DOK7 · GFPT1), type including distal involvement (slow-channel). Severe muscle atrophy is observed in chronically progressive subtypes.

Tendon reflexes: Reduced or normal; absent in severe cases. The sensory system is preserved as normal.

Paradoxical worsening in COLQ type: A paradoxical response in which symptoms transiently worsen after administration of an AChE inhibitor (pyridostigmine) is a diagnostic clue to the COLQ type. AChE inhibitors are absolutely contraindicated in this subtype.

Respiratory signs: Reduced chest wall movement, use of accessory respiratory muscles, and a paradoxical breathing pattern are observed in severe cases. Hypoxemia during sleep may appear first.

8. Screening

Screening for CMS begins with clinical suspicion. CMS is considered when the following combination is present: hypotonia or fatigable weakness with onset in the neonatal period to childhood, family history, worsening with fever · infection, and negative autoantibodies.

Autoantibody testing first: Serum AChR antibodies and MuSK antibodies are tested first to confirm negativity. CMS is actively suspected in autoantibody-negative pediatric myasthenic syndromes.

Electrophysiological testing: Decremental response confirmed on repetitive nerve stimulation (RNS). Increased jitter on single-fiber electromyography (SFEMG). Doublet CMAP discharges in response to a single stimulus are characteristic of slow-channel syndrome.

Genetic testing: CMS panel NGS testing is currently the standard. More than 35 genes are analyzed simultaneously. If the panel is negative, whole exome (WES) or whole genome sequencing (WGS) is considered.

Ultrastructural analysis of the neuromuscular junction: Electron microscopic and histochemical analysis (including AChE staining) of a muscle biopsy. It was the standard before the era of genetic testing, but is now performed selectively in cases where genetic confirmation is difficult.

9. Diagnosis

CMS is diagnosed by integrating clinical, electrophysiological, and genetic testing. Negative autoantibodies are a required condition.

Serological tests: Confirm that AChR, MuSK, and LRP4 antibodies are all negative. Rarely, double positivity (autoimmune MG + CMS) has been reported, so results must be interpreted in the clinical context.

Electrophysiological testing: Repetitive nerve stimulation test (decremental response at 3 Hz stimulation), single-fiber electromyography (increased jitter), doublet discharges in slow-channel syndrome. In children, electrophysiological testing is technically difficult and requires cooperation.

NGS gene panel testing: Currently the most efficient method of confirmation. Major panels include CHRNA1, CHRNB1, CHRND, CHRNE, RAPSN, COLQ, DOK7, MUSK, LRP4, CHAT, SLC5A7, GFPT1, GMPPB, ALG2, ALG14, DPAGT1, etc.

Neuromuscular junction analysis (optional): Subtype classification by electron microscopic ultrastructural analysis, microelectrode electrophysiology (measurement of MEPP amplitude and frequency), and AChE histochemical staining of a muscle biopsy. Now that genetic testing has become readily available, it is performed mainly for research purposes or in cases with an unknown gene.

10. Treatment

Treatment of CMS differs completely depending on the causative gene and pathophysiological subtype. Inappropriate treatment (e.g., AChE inhibitors in the COLQ type) can actually worsen the clinical course, so the principle is to decide on treatment after genetic confirmation.

AChE inhibitors (pyridostigmine · neostigmine): Effective in subtypes with AChR deficiency or reduced synaptic ACh, such as CHRNE, RAPSN, CHAT, and fast-channel syndrome (some). They are generally tried empirically as first-line treatment for CMS, but the response must always be monitored. Typical dose: pyridostigmine 30–60 mg every 4–6 hours.

Albuterol (salbutamol) or ephedrine: Established as the first-line standard treatment in the DOK7 type. It promotes MuSK activation and AChR clustering through beta-2 adrenergic receptor action. Significantly superior effect to AChE inhibitors in the DOK7 type. Ephedrine: 25–50 mg/day; salbutamol: 4 mg × 2–3 times/day (pediatric 0.1 mg/kg). Salbutamol may also be effective in some glycosylation defect subtypes such as the GFPT1 type.

3,4-Diaminopyridine (3,4-DAP): Effective in presynaptic defect subtypes (CHAT type, paucity of synaptic vesicles, etc.) by increasing ACh release. It is sometimes combined with pyridostigmine. Dose: 5–20 mg 3–4 times/day.

Quinidine or fluoxetine: Used as channel blockers that shorten AChR channel opening time in slow-channel syndrome. Quinidine: 200–300 mg 3–4 times/day. Monitoring for cardiac toxicity is required. Fluoxetine: used as an alternative at some centers.

Treatment of COLQ type: AChE inhibitors are absolutely contraindicated. Salbutamol or ephedrine may produce clinical improvement in some patients.

Supportive care: Noninvasive ventilation (NIV) for nocturnal hypoxemia · sleep apnea, mechanical ventilation for respiratory failure, physical therapy · occupational therapy, swallowing rehabilitation. Prompt antibiotic treatment and respiratory support during fever · infection.

11. Prognosis

The prognosis of CMS varies greatly depending on the causative gene and subtype. In most subtypes, functional improvement is possible with appropriate treatment, but complete remission is rare and lifelong treatment is required.

The CHRNE and RAPSN types can maintain relatively good function with AChE inhibitors. The DOK7 type has been reported to show marked functional improvement with salbutamol/ephedrine treatment, but muscle atrophy that has already developed before treatment tends not to recover. In slow-channel syndrome, chronic endplate damage accumulates and irreversible muscle atrophy may progress. The CHAT type has recurrent episodic respiratory crises and sometimes requires long-term respiratory support. The COLQ type varies in severity, and some patients respond to salbutamol.

Even in adulthood, most CMS patients show a stable or slowly progressive course under appropriate treatment. Regular respiratory function assessment (FVC, nocturnal oxygen saturation monitoring) is important. Because life-threatening respiratory crises can occur especially during infection · fever, an emergency plan (emergency letter) is always provided to the patient.

12. Prevention

Because CMS is a hereditary disease, the key is genetic counseling, early diagnosis, and accurate treatment after subtype confirmation, rather than prevention of the disease itself.

Genetic counseling: The recurrence risk according to the mode of inheritance is explained to families of confirmed CMS patients, and genetic testing is offered. In AR inheritance, the parents are carriers and the risk to siblings is 25%. In high-risk families, prenatal diagnosis (DNA analysis using amniocentesis or chorionic villus sampling) or preimplantation genetic diagnosis (PGD) is possible.

Early neonatal detection: Life-threatening respiratory crises can be prevented by suspecting CMS early in infants with neonatal hypotonia or feeding difficulty and promptly proceeding with autoantibody and genetic testing.

No empirical treatment without subtype confirmation: Empirical administration of AChE inhibitors can cause paradoxical worsening in the COLQ type. Therefore, if treatment must be started before genetic confirmation, a small dose is given and the response is closely observed to determine whether worsening occurs.

Avoidance of aggravating factors: Prompt treatment of fever · infection, avoidance of magnesium · aminoglycosides · neuromuscular blockers, and informing the anesthesiologist of CMS in advance of surgery are important.

References

  1. Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(4):420-434. PMID: 25792100
  2. Estephan EP, Zambon AA. Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes — A Comprehensive Review. J Neuromuscul Dis. 2023;10(1):1-23. PMID: 36806510
  3. Natera-de Benito D, Bestue M, Dominguez-Carral J, et al. Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis. Brain. 2024;147(11):3849-3861. DOI: 10.1093/brain/awae229
  4. Barisic N, Chaouch A, Muller JS, et al. Genetic aspects of myasthenia and congenital myasthenic syndromes. J Neurol. 2011;258(7):1166-1172. PMID: 21562896
  5. Palace J, Beeson D. The congenital myasthenic syndromes. J Neuroimmunol. 2008;201-202:2-5. PMID: 18682317
  6. Abicht A, Dusl M, Gallenmüller C, et al. Congenital myasthenic syndromes: achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice. Hum Mutat. 2012;33(10):1474-1484. PMID: 22678886
  7. Ramdas S, Beeson D. Congenital myasthenic syndromes: where do we stand and what is on the horizon? Neuromuscul Disord. 2021;31(9):885-896. PMID: 34544638
  8. Finlayson S, Palace J, Belaya K, et al. Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. J Neurol Neurosurg Psychiatry. 2013;84(10):1119-1125. PMID: 23661650
  9. Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve. 2011;44(5):789-794. PMID: 22006445
  10. Natera-de Benito D, Nascimento A, Abicht A, et al. KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors. J Neurol. 2016;263(2):268-274. PMID: 26659861